Why the study?
Does elevated troponin I on admission predict adverse outcomes in patients with AMI undergoing primary angioplasty?
Does elevated troponin I on admission predict adverse outcomes in patients with AMI undergoing primary angioplasty?
Elevated troponin I on admission in STEMI/LBBB patients undergoing primary angioplasty is associated with lower rates of TIMI 3 flow and higher rates of adverse clinical outcomes.
Answers are grounded in this paper and cite their sources.
Elevated admission cTnI flags higher-risk STEMI patients for failed reperfusion and adverse events; leaves open whether troponin-guided strategies improve primary angioplasty outcomes.
BACKGROUND: In patients with acute myocardial infarction (AMI) undergoing thrombolytic therapy, an elevated troponin level on admission is associated with a lower reperfusion rate and a complicated clinical course. Whether an elevated troponin level on admission similarly predicts an adverse outcome in patients undergoing primary angioplasty is currently unknown and was investigated in the present study. METHODS AND RESULTS: Cardiac troponin I (cTnI) was determined on admission in 110 consecutive patients with AMI associated with ST-segment elevation or left bundle branch block who underwent primary angioplasty. Fifty-four patients (49%) had an elevated cTnI (>/=0.4 ng/mL) on admission. In patients with elevated cTnI, primary angioplasty was less likely to achieve TIMI 3 flow (as classified by the Thrombolysis in Myocardial Infarction trial) in univariate (76% versus 96%, P:=0.03) or in multivariate (odds ratio 0.1, 95% CI 0.02 to 0.54) analysis. Patients with elevated cTnI were more likely to develop congestive heart failure (23% versus 9%, P:<0.05) and death, heart failure, or shock (30% versus 9%, P:=0.006). Elevated cTnI remained a significant predictor of the composite end point after controlling for other clinical data that were available early in the course, including time to presentation and angiographic results (relative risk 5.2, 95% CI 1.03 to 26.3). During a follow-up of 426+/-50 days, elevated admission cTnI was a predictor of cardiac mortality (11% versus 0%, P:=0.012), adverse cardiac events (cardiac mortality or nonfatal reinfarction; 19% versus 5.4%, P:=0.04), and adverse cardiac events plus target vessel revascularization (32% versus 14%, P:=0.054). CONCLUSIONS: In patients with ST-segment elevation AMI, an elevated cTnI on admission is associated with an increased risk of primary angioplasty failure and a more complicated clinical course.
No takes yet. Share an insight, caveat, or question.
Matetzky et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: